XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 15,085,643 $ 23,786,579
Short-term investments 80,509,364 103,638,844
Accounts receivable 1,712,962 6,003,205
Accounts receivable from affiliated entities 960,453 486,619
Prepaid expenses and other current assets 1,785,081 2,600,906
Prepaid expenses and other current assets from affiliated entities 1,787,297 1,846,007
Total current assets 101,840,800 138,362,160
Fixed assets, net 16,868,953 18,320,176
Investment in affiliated entity - GeneOne 9,014,490 9,069,401
Investment in affiliated entity - PLS 2,667,805 2,325,079
Intangible assets, net 5,293,271 6,009,729
Goodwill 10,513,371 10,513,371
Other assets 2,724,376 2,639,354
Total assets 148,923,066 187,239,270
Current liabilities:    
Accounts payable and accrued expenses 12,609,959 23,278,798
Accounts payable and accrued expenses due to affiliated entities 600,701 926,943
Accrued clinical trial expenses 10,359,872 8,611,892
Common stock warrants 228,665 360,795
Deferred revenue 762,361 1,175,353
Deferred revenue from affiliated entities 55,125 174,110
Deferred rent 979,803 877,535
Deferred grant funding 2,620,985 0
Deferred grant funding from affiliated entities 188,800 0
Total current liabilities 28,406,271 35,405,426
Deferred revenue, net of current portion 175,157 215,853
Deferred rent, net of current portion 8,825,052 9,104,416
Deferred tax liabilities 24,766 24,766
Total liabilities 37,431,246 44,750,461
Stockholders’ equity:    
Preferred stock 0 0
Common stock 91,474 90,358
Additional paid-in capital 674,017,367 665,775,504
Accumulated deficit (562,114,904) (523,356,317)
Accumulated other comprehensive loss (598,386) (117,005)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 111,395,551 142,392,540
Non-controlling interest 96,269 96,269
Total stockholders’ equity 111,491,820 142,488,809
Total liabilities and stockholders’ equity $ 148,923,066 $ 187,239,270